[1st Expert Panel on viper venomous bite in Spain]

Amate Blanco JM, Bouza Álvarez C, Conde Espejo P, Chippaux JP, De Haro L, Del Pino Luengo M, Estefanía Díaz ME, García Ubbelohde W, García Willis C, Lisa Catón V, Martín Sierra MC, Méndez García JL, Nogué Xarau S, Oteo JA, Palomar AM, Saz Parkinson Z
Record ID 32013000273
Authors' objectives: In Europe, snakebites are rare medical emergency cases, but they are sometimes severe and with complications. Despite a great and wide health care offer, a better understanding of the epidemiology of the ophidian poisoning as well as the diverse therapeutic management would help to know the gaps and the opportunities to precise the most urgent needs. A good way to achieve the objective is carrying an expert meeting on the issue.
Authors' recommendations: According to the experts children and males are population more affected by snakebite. The bites occur mainly in rural areas and are connected with agricultural, pleasure and/or sport activities. They usually happen in spring and summer seasons. The clinical symptoms of viper bites are homogenous throughout Europe. For the evaluation of the viper bite at a continental level, there is a certain consensus in using the gradation table published in 1992 by Audebert et al with a scale from grade 0 to III. All snake bite requires medical assistance. The clinical management in Spain is very similar in every hospital. Depending on the clinical features and the severity of the bite, analgesic and update antitetanus can be applied until grade I, then keep observing the symptoms evolution. If the patient presents grade II or III, the administration of the antivenom must be asses. Prompt use of the antivenom is recommended, if it is possible before the ten hours after the bite, and always intravenous. Inmunotherapy indications would be particularly important in children and pregnant woman because of the increased risk of venom complications within these vulnerable populations, due to the excellent tolerance for newer antivenoms. Nowadays four are the antivenoms commercialized in four countries in Europe.Depending on the countries, these products are available within the hospital environment or in pharmacies with or without distribution restrictions. However, although its indication is an object of a general consensus, several elements, such as the doses and the time limits for the administration not registered properly, explains the limits of distribution among the european countries as well as a heterogeneous utilization.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Humans
  • Viper Venoms
  • Snake Bites
  • Spain
Organisation Name: Agencia de Evaluacion de Tecnologias Sanitarias
Contact Address: Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;
Contact Name: Luis M. Sánchez Gómez
Contact Email: luism.sanchez@isciii.es
Copyright: Agencia de Evaluacion de Tecnologias Sanitarias (AETS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.